Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus anlotinib for unresectable locally advanced head and neck adenoid cystic carcinoma
ChiCTR2500111505Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Adenoid cystic carcinoma (ACC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Local control rate, Distant disease-free survival rate and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on ChiCTR2500111505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111505.